Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors
Authors: Mahaboobi Jaleel, Ramesh S. Senaiar, Chandrasekhar Abbineni, Girish A. Renukappa, Subhendu Mukherjee, Sivapriya Marappan, DS Samiulla, AB Aravind, Naveen R. Kumar, Venkata Siva N. Reddy, Asha Babu, Akhila P. Srinivas, Prasad Yadlapalli, Suraj Tgore, Raghavendra NR, Chandranath D. Naik, Sanjeev Giri, Thomas Antony, Kavitha Nellore, Shekar Chelur, Girish Daginakatte, laura Ravanti, Mikko Myllymäki, Gerd Wohlfahrt, Elina Mattila, Stefan Karlsson, Mari Björkman, Reetta Riikonen, Tarja Ikonen, Laura Leimu, Chira Mälmström, Timo Korjamo, Anu Moilanen, Murali Ramachandra, Susanta Samajdar
Journal: Cancer Research (2020)

Abstract Background: The Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins are key regulators of epigenetic control. Although pan BET Inhibitors show good clinical activity, progressive disease was seen after several months of treatment in clinical responders, likely due to secondary resistance mechanisms. The plausible resistance mechanisms are increased expression of TCF7L2, c-Myc, Survivin and PIM1. Cyclic AMP response element binding protein (CREB)-binding protein (CBP) and E1A interacting protein of 300 kDa (EP300 or p300) are two closely related histone acetyl transferases with oncogenic roles in a variety of cancers. They are known to be co-activators of several key transcription factors that contribute to tumor progression including HIF1a, BRCA-1, p53, c-Myc and androgen receptor (AR). Studies have indicated that p300 is also upregulated in SPOP-mutated prostate cancer. Thus, targeting CBP/p300 represents an attractive approach for developing novel therapies. Methods and Results: Multiple potent and selective CBP/p300 bromodomain inhibitors that are structurally unrelated to known inhibitors were identified by iterative medicinal chemistry and SAR based approaches. The compounds were optimized towards attaining good physicochemical properties and DMPK profile. The anti-proliferative activity of the lead compounds was studied across multiple tumor types in a 3-day assay. The lead compounds potently inhibited viability of a wide range of hematological and solid tumor cell lines including prostate cancer cell lines VCaP and 22Rv1. In H929 cell line the lead compounds showed dose-dependent inhibition of cMYC and increase in cPARP. In a single dose PK-PD study in MV4-11 xenograft model, the compounds showed modulation of cMYC and Survivin. Conclusions: In summary, our studies demonstrate that selective CBP/p300 bromodomain inhibitors are potent in models of hematologic malignancies and solid tumors in-vitro. Profiling of efficacy in xenograft models, and further toxicological evaluation are in progress. Citation Format: Mahaboobi Jaleel, Ramesh S. Senaiar, Chandrasekhar Abbineni, Girish A. Renukappa, Subhendu Mukherjee, Sivapriya Marappan, DS Samiulla, AB Aravind, Naveen R. Kumar, Venkata Siva N. Reddy, Asha Babu, Akhila P. Srinivas, Prasad Yadlapalli, Suraj Tgore, Raghavendra NR, Chandranath D. Naik, Sanjeev Giri, Thomas Antony, Kavitha Nellore, Shekar Chelur, Girish Daginakatte, laura Ravanti, Mikko Myllymäki, Gerd Wohlfahrt, Elina Mattila, Stefan Karlsson, Mari Björkman, Reetta Riikonen, Tarja Ikonen, Laura Leimu, Chira Mälmström, Timo Korjamo, Anu Moilanen, Murali Ramachandra, Susanta Samajdar. Targeting cancer with selective cbp/p300 bromodomain inhibitors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1753.